Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06105632




Registration number
NCT06105632
Ethics application status
Date submitted
24/10/2023
Date registered
27/10/2023
Date last updated
19/11/2024

Titles & IDs
Public title
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Scientific title
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY
Secondary ID [1] 0 0
2023-506487-13-00
Secondary ID [2] 0 0
C4391022
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced or Metastatic Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PF-07220060 CDK4 inhibitor
Treatment: Drugs - Fulvestrant
Treatment: Drugs - Everolimus
Treatment: Drugs - Exemestane

Experimental: Arm A - PF-07220060 to be taken by mouth as a tablet in combination with fulvestrant (a solution for injection)

Active comparator: Arm B - Investigator's choice of therapy of either:

* Fulvestrant alone (a solution for injection), or
* Everolimus in combination with exemestane, both a tablet to be taken by mouth.


Treatment: Drugs: PF-07220060 CDK4 inhibitor
Experimental

Treatment: Drugs: Fulvestrant
Experimental and Active comparator

Treatment: Drugs: Everolimus
Active Comparator

Treatment: Drugs: Exemestane
Active Comparator
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS) progression, as determined by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Timepoint [1] 0 0
From Initiation up to 2 years
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Time from the date of randomization to the date of death due to any cause up to approximately 5 years
Secondary outcome [2] 0 0
PFS as defined by investigator
Timepoint [2] 0 0
Time from the date of randomization up to approximately 2 years
Secondary outcome [3] 0 0
OR by BICR and by investigator per RECIST v1.1
Timepoint [3] 0 0
Time From randomization date (every 8 weeks during the first 48 weeks and then every 12 weeks) to the date of progression OR death whichever occurs first (up to approximately 2 years)
Secondary outcome [4] 0 0
Duration of Response (DOR) as define by Blinded Independent Central Review (BICR) and by investigator per RECIST v1.1
Timepoint [4] 0 0
From the date of the first objective response (every 8 weeks during the first 48 weeks and then every 12 week) up to approximately 2 years.
Secondary outcome [5] 0 0
Number of Participants With Clinical Benefit Response (CBR) by BICR and by investigator per RECIST v1.1
Timepoint [5] 0 0
From randomization date (every 8 weeks during the first 48 weeks and then every 12 weeks) up to approximately 2 years
Secondary outcome [6] 0 0
Number or Patients with Adverse Events (AEs) by Type
Timepoint [6] 0 0
From screening until 28 days after the last dose, to approximately 3 years
Secondary outcome [7] 0 0
Number or Patients with AEs by Incidence
Timepoint [7] 0 0
From screening until 28 days after the last dose, to approximately 3 years
Secondary outcome [8] 0 0
Number or Patients with AEs by Seriousness
Timepoint [8] 0 0
From screening until 28 days after the last dose, to approximately 3 years
Secondary outcome [9] 0 0
Number or Patients with AEs by relationship to study interventions
Timepoint [9] 0 0
From screening until 28 days after the last dose, to approximately 3 years
Secondary outcome [10] 0 0
Number of Participants With Abnormal Electrocardiogram (ECG)
Timepoint [10] 0 0
From baseline to approximately 2 years
Secondary outcome [11] 0 0
Number of Participants With Laboratory Test Abnormalities
Timepoint [11] 0 0
From screening until 28 days after the last dose to approximately 2 years
Secondary outcome [12] 0 0
EQ-5D-5L
Timepoint [12] 0 0
Screening Days 1, 15 of Cycle 1 and 2, Day 1 of Cycles 3-6, then Day 1 of every other subsequent Cycle starting with Cycle 8 (eg, Cycles 8, 10, 12, etc), EoT and Safety FU until 28 days after the last dose to approximately 2 years. Each Cycle is 28 days
Secondary outcome [13] 0 0
EORTC QLQ
Timepoint [13] 0 0
Screening Days 1, 15 of Cycle 1 and 2, Day 1 of Cycles 3-6, then Day 1 of every other subsequent Cycle starting with Cycle 8 (eg, Cycles 8, 10, 12, etc), EoT and Safety FU until 28 days after the last dose to approximately 2 years. Each Cycle is 28 days
Secondary outcome [14] 0 0
EORTC QLQ Breast Cancer Module 23 (BR23)
Timepoint [14] 0 0
Screening Days 1, 15 of Cycle 1 and 2, Day 1 of Cycles 3-6, then Day 1 of every other subsequent Cycle starting with Cycle 8 (eg, Cycles 8, 10, 12, etc), EoT and Safety FU until 28 days after the last dose to approximately 2 years. Each Cycle is 28 days
Secondary outcome [15] 0 0
Ctrough of PF-07220060
Timepoint [15] 0 0
Cycle 1 (Day 15), Cycle 2 (Day 1), and Cycle 3 (Day 1). Each Cycle is 28 days

Eligibility
Key inclusion criteria
* Histological confirmation of breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent.
* Documented estrogen receptor (ER) and/or progesterone receptor (PR)- positive tumor
* Documented HER2-negative tumor
* Able to provide a sufficient amount of representative formalin fixed, paraffin embedded (FFPE) tumor tissue specimen.
* Must have received CDK4/6i plus NSAI defined per study protocol. There must be documented PD during or after CDK4/6i treatment.
* Measurable disease or non-measurable bone only disease as defined by RECIST version 1.1.
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) =2.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any medical or psychiatric condition that may increase the risk of study participation or make the participant inappropriate for the study.
* In visceral crisis at risk of immediately life-threatening complications in the short term.
* Known active uncontrolled or symptomatic central nervous system metastases, carcinomatous meningitis, or leptomeningeal disease.
* Prior treatment with any of the following:
* Everolimus or investigational anti-cancer agents in any setting
* Prior chemotherapy in the advanced setting
* Radiation within 2 weeks of randomization
* Current use or anticipated need for any prohibited food, supplements or concomitant medication(s) (ie, other anti-cancer therapies, other endocrine therapies, growth factors, chronic systemic corticosteroids, strong cytochrome P450 3A4/5 [CYP3A4/5] or uridine 5' diphosphate-glucuronosyltransferase 2B7 [UGT2B7] inhibitors and inducers, direct oral anticoagulants, proton pump inhibitors).
* Inadequate renal function, hepatic dysfunction, or hematologic abnormalities.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/01/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
8/12/2028
Actual
Sample size
Target
500
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
Macquarie University - North Ryde
Recruitment hospital [2] 0 0
Icon Cancer Centre Townsville - Rosslea
Recruitment hospital [3] 0 0
Icon Cancer Centre Townsville - Townsville
Recruitment postcode(s) [1] 0 0
2109 - North Ryde
Recruitment postcode(s) [2] 0 0
4812 - Rosslea
Recruitment postcode(s) [3] 0 0
4812 - Townsville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Mississippi
Country [10] 0 0
United States of America
State/province [10] 0 0
Montana
Country [11] 0 0
United States of America
State/province [11] 0 0
Nevada
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Virginia
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
United States of America
State/province [17] 0 0
Wisconsin
Country [18] 0 0
Argentina
State/province [18] 0 0
Buenos Aires
Country [19] 0 0
Argentina
State/province [19] 0 0
Ciudad Autónoma DE Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
RÍO Negro
Country [21] 0 0
Argentina
State/province [21] 0 0
Santa FE
Country [22] 0 0
Argentina
State/province [22] 0 0
Tucumán
Country [23] 0 0
Argentina
State/province [23] 0 0
Ciudad Autónoma Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Ciudad Autónoma de Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Córdoba
Country [26] 0 0
Argentina
State/province [26] 0 0
La Rioja
Country [27] 0 0
Argentina
State/province [27] 0 0
Santiago del Estero
Country [28] 0 0
Brazil
State/province [28] 0 0
Bahia
Country [29] 0 0
Brazil
State/province [29] 0 0
Ceará
Country [30] 0 0
Brazil
State/province [30] 0 0
Pernambuco
Country [31] 0 0
Brazil
State/province [31] 0 0
RIO Grande DO Norte
Country [32] 0 0
Brazil
State/province [32] 0 0
RIO Grande DO SUL
Country [33] 0 0
Brazil
State/province [33] 0 0
SÃO Paulo
Country [34] 0 0
Canada
State/province [34] 0 0
New Brunswick
Country [35] 0 0
Canada
State/province [35] 0 0
Nova Scotia
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec
Country [38] 0 0
Chile
State/province [38] 0 0
Región Metropolitana DE Santiago
Country [39] 0 0
China
State/province [39] 0 0
Anhui
Country [40] 0 0
China
State/province [40] 0 0
Beijing
Country [41] 0 0
China
State/province [41] 0 0
Chongqing
Country [42] 0 0
China
State/province [42] 0 0
Guangdong
Country [43] 0 0
China
State/province [43] 0 0
Guangxi
Country [44] 0 0
China
State/province [44] 0 0
Heilongjiang
Country [45] 0 0
China
State/province [45] 0 0
Henan
Country [46] 0 0
China
State/province [46] 0 0
Hubei
Country [47] 0 0
China
State/province [47] 0 0
Hunan
Country [48] 0 0
China
State/province [48] 0 0
Jiangsu
Country [49] 0 0
China
State/province [49] 0 0
Jilin
Country [50] 0 0
China
State/province [50] 0 0
Liaoning
Country [51] 0 0
China
State/province [51] 0 0
Shaanxi
Country [52] 0 0
China
State/province [52] 0 0
Shanghai
Country [53] 0 0
China
State/province [53] 0 0
Sichuan
Country [54] 0 0
China
State/province [54] 0 0
Tianjin
Country [55] 0 0
China
State/province [55] 0 0
Zhejiang
Country [56] 0 0
India
State/province [56] 0 0
Delhi
Country [57] 0 0
India
State/province [57] 0 0
Gujarat
Country [58] 0 0
India
State/province [58] 0 0
Karnataka
Country [59] 0 0
India
State/province [59] 0 0
Maharashtra
Country [60] 0 0
India
State/province [60] 0 0
Rajasthan
Country [61] 0 0
India
State/province [61] 0 0
WEST Bengal
Country [62] 0 0
Israel
State/province [62] 0 0
Hadarom
Country [63] 0 0
Israel
State/province [63] 0 0
Hamerkaz
Country [64] 0 0
Israel
State/province [64] 0 0
Hatsafon
Country [65] 0 0
Israel
State/province [65] 0 0
Yerushalayim
Country [66] 0 0
Japan
State/province [66] 0 0
Aichi
Country [67] 0 0
Japan
State/province [67] 0 0
Chiba
Country [68] 0 0
Japan
State/province [68] 0 0
Ehime
Country [69] 0 0
Japan
State/province [69] 0 0
Gunma
Country [70] 0 0
Japan
State/province [70] 0 0
Hokkaido
Country [71] 0 0
Japan
State/province [71] 0 0
Miyagi
Country [72] 0 0
Japan
State/province [72] 0 0
Osaka
Country [73] 0 0
Japan
State/province [73] 0 0
Saitama
Country [74] 0 0
Japan
State/province [74] 0 0
Shizuoka
Country [75] 0 0
Japan
State/province [75] 0 0
Tokyo
Country [76] 0 0
Japan
State/province [76] 0 0
Hiroshima
Country [77] 0 0
Japan
State/province [77] 0 0
Kumamoto
Country [78] 0 0
Japan
State/province [78] 0 0
Okayama
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Incheon-gwangyeoksi [incheon]
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Kyonggi-do
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Pusan-kwangyokshi
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Seoul-teukbyeolsi [seoul]
Country [83] 0 0
Korea, Republic of
State/province [83] 0 0
Taegu-kwangyokshi
Country [84] 0 0
Mexico
State/province [84] 0 0
Distrito Federal
Country [85] 0 0
Mexico
State/province [85] 0 0
Jalisco
Country [86] 0 0
Mexico
State/province [86] 0 0
Nuevo LEÓN
Country [87] 0 0
Mexico
State/province [87] 0 0
Chihuahua
Country [88] 0 0
Mexico
State/province [88] 0 0
Oaxaca
Country [89] 0 0
Mexico
State/province [89] 0 0
Veracruz
Country [90] 0 0
Switzerland
State/province [90] 0 0
Aargau
Country [91] 0 0
Switzerland
State/province [91] 0 0
Olten
Country [92] 0 0
Taiwan
State/province [92] 0 0
Taichung
Country [93] 0 0
Taiwan
State/province [93] 0 0
Tainan
Country [94] 0 0
Taiwan
State/province [94] 0 0
Taipei
Country [95] 0 0
Taiwan
State/province [95] 0 0
Taoyuan
Country [96] 0 0
Turkey
State/province [96] 0 0
I?stanbul
Country [97] 0 0
Turkey
State/province [97] 0 0
I?zmir
Country [98] 0 0
Turkey
State/province [98] 0 0
Ankara
Country [99] 0 0
Turkey
State/province [99] 0 0
Diyarbakir
Country [100] 0 0
Turkey
State/province [100] 0 0
Kayseri
Country [101] 0 0
Turkey
State/province [101] 0 0
Kocaeli
Country [102] 0 0
Turkey
State/province [102] 0 0
Konya
Country [103] 0 0
Turkey
State/province [103] 0 0
Samsun
Country [104] 0 0
United Kingdom
State/province [104] 0 0
England
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Hammersmith AND Fulham
Country [106] 0 0
United Kingdom
State/province [106] 0 0
London, CITY OF
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Midlothian
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Warwickshire
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Guildford
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Manchester
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Swindon

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body.

This study is seeking female and male participants who:

* are 18 years of age or older;
* are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative;
* have advanced or metastatic breast cancer after taking other treatments before this study;
* have not taken or need to take medications that are not allowed by the study protocol;
* do not have any medical or mental conditions that may increase the risk of study participation.

Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be:

* Fulvestrant alone taken as shot into the muscle.
* Everolimus along with exemestane taken once daily by mouth.

This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective.

Participants will receive study treatment and/or will be in the study until:

* imaging scans (such as an MRI and/or CT) show that their cancer is getting worse.
* the study doctor thinks the participant is no longer benefitting from the study medicine.
* has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take.
* the participant chooses to stop taking part.
Trial website
https://clinicaltrials.gov/study/NCT06105632
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Country 0 0
Phone 0 0
1-800-718-1021
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06105632